Key facts
- This page summarizes Eric Easom's Form 3 filing for AN2 Therapeutics, Inc. (ANTX).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Mar 2022, 21:19.
Eric Easom - 24 Mar 2022 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ANTX
- Reported as of
- 24 Mar 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 24 Mar 2022, 21:19:22 UTC
- Next SEC filing
- 31 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lucy Day, Attorney-in-Fact for Eric Easom
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eric Easom filed Form 3 for AN2 Therapeutics, Inc. (ANTX) on 24 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,099,997
- Date
- 24 Mar 2022
- Ownership
- By Easom Living Trust
ANTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 194,116
- Date
- 24 Mar 2022
- Ownership
- By Children Trusts
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANTX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 249,999
- Exercise price
- $6.60
- Footnotes
- F2
ANTX
holding
Derivative
Series A Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,907
- Exercise price
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These shares are held in trusts for the benefit of the Reporting Person's children. Represents 97,058 shares held by the C. EASOM IRREVOCABLE TRUST dated October 8, 2021 and 97,058 shares held by the JUDE EASOM IRREVOCABLE TRUST dated October 8, 2021 (collectively, the "Children Trusts"), for which the Reporting Person and his spouse are trustees.
Footnote F2
The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.
Footnote F3
Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
SEC remarks
Exhibit 24 - Power of Attorney